Carolyn Kay, MD, discusses the latest ASCCP guidelines and the introduction of dual stain cytology for improved HPV detection and patient management, aiming to alleviate anxiety and enhance efficacy in cervical cancer prevention.
In a recent interview, Carolyn Kay, MD, medical affairs lead at Roche Diagnostics, discussed new ASCCP guidelines about cervical cancer management.
Patients will often feel anxiety when HPV is detected in their system. This anxiety often relates to having to wait a year before coming back and getting retested. Kay expressed feeling a similar anxiety at times because of not always knowing if the patient would come back for additional testing.
Often, Kay would have patients who did not have precancerous lesions needing intervention for multiple years in a row. She noticed the repeated testing led to anxiety and frustration in some patients.
With the new tool, clinicians will be able to determine if an HPV infection is leading to precancerous changes on a molecular level. This will also lead to greater efficacy for identifying patients who should be recommended to receive a coloscopy. Guidance from the ASCCP will help clinicians manage cases where HPV is detected.
The new method for managing patients with HPV is referred to as dual stain cytology. It detects the P-16 and KI-67 biomarkers that indicate cell cycle rest and cell cycle progression, respectively. When both markers are detected in the same cell, this indicates cell cycle dysregulation and is associated with precancerous changes on the cervix.
Since the 1970’s, cervical cancer incidence has decreased by over half in the United States. This decrease is because of guidelines for managing precancerous conditions, but more work is necessary to reduce disparities in the health care system, according to Kay.
Kay believes the dual stain will simplify decision making, with increased accuracy compared to the current standard of care. It requires fewer coloscopies and detects cervical intraepithelial neoplasia stage 3 earlier compared to the current standard of care.
While progress has been made, cervical cancer is not decreasing equally across US populations, with patients still dying from this preventable disease. Kay concluded by stating providers should consider how different communities are impacted by these new technologies.
Study finds reduced CIN3+ risk from early HPV vaccination
April 16th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
Read More
Assessing Onclarity HPV assay safety and efficacy for cervical cancer screening
February 21st 2024A recent study evaluated the safety and effectiveness of the Onclarity HPV assay in detecting high-grade cervical disease, presenting findings on its comparability to predicate assays and potential for cost-saving benefits in screening practices.
Read More
Unifying radical hysterectomy classifications with the Querleu-Morrow
February 16th 2024Explore how the latest research underscores the efficacy of the 2017 Querleu-Morrow classification in defining radical hysterectomy extent, shedding light on surgical terminologies for cervical cancer management.
Read More
Protecting HIV-positive adolescents against high-risk HPV types
February 5th 2024A recent study found that the Gardasil quadrivalent HPV vaccine effectively shields HIV-positive adolescents from high-risk HPV types 16, 18, 6, and 11, shedding light on the potential for HPV vaccination to mitigate cancer risks in this vulnerable population.
Read More